TherapeuticsMD (TXMD)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	5.75 mm	5.75 mm	5.75 mm	5.75 mm	5.75 mm	5.75 mm
Cash burn (monthly)	(no burn)	(no burn)	290.33 k	374.08 k	(no burn)	(no burn)
Cash used (since last report)	n/a	n/a	813.17 k	1.05 mm	n/a	n/a
Cash remaining	n/a	n/a	4.93 mm	4.70 mm	n/a	n/a
Runway (months of cash)	n/a	n/a	17.0	12.6	n/a	n/a

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2024

TXMD institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	42	39	+7.7%
Opened positions	7	26	-73.1%
Closed positions	4	1	+300.0%
Increased positions	4	1	+300.0%
Reduced positions	5	0	NEW

13F shares	Current	Prev Q	Change
Total value	3.06 bn	5.63 bn	-45.7%
Total shares	35.55 mm	35.40 mm	+0.4%
Total puts	4.40 k	7.10 k	-38.0%
Total calls	16.40 k	4.50 k	+264.4%
Total put/call ratio	0.3	1.6	-83.0%

Largest owners	Shares	Value	Change
Flynn James E	20.66 mm	$23.14 mm	0.0%
Smith Robert J	11.35 mm	$0.00	0.0%
Rubric Capital Management	1.19 mm	$1.03 bn	0.0%
Clearline Capital	635.22 k	$546.29 mm	-0.2%
Tejara Capital	394.66 k	$339.41 mm	-1.7%
Vanguard	387.58 k	$333.32 mm	0.0%
ADAR1 Capital Management	270.16 k	$232.34 mm	0.0%
Citadel Advisors	145.80 k	$125.40 mm	NEW
MS Morgan Stanley	132.39 k	$113.86 mm	+0.5%
BlackRock	116.13 k	$99.87 mm	0.0%

Largest transactions	Shares	Bought/sold	Change
Citadel Advisors	145.80 k	+145.80 k	NEW
Renaissance Technologies	10.89 k	+10.89 k	NEW
Tejara Capital	394.66 k	-6.79 k	-1.7%
UBS UBS	2.01 k	-2.84 k	-58.5%
Tower Research Capital	4.78 k	+2.51 k	+110.4%
Clearline Capital	635.22 k	-1.40 k	-0.2%
Group One Trading	1.14 k	+1.14 k	NEW
MS Morgan Stanley	132.39 k	+670.00	+0.5%
Capital Performance Advisors	0.00	-600.00	EXIT
SBI Securities	255.00	+255.00	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

TXMD insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
14 Apr 25	Marlan D Walker	Common Stock	Buy	Acquire P	No	No	0.9985	490	489.27	73,639
14 Apr 25	Tommy G Thompson	Common Stock	Buy	Acquire P	No	No	1.0018	325	325.58	14,779
10 Apr 25	Marlan D Walker	Common Stock	Buy	Acquire P	No	No	0.8572	1,167	1.00 k	73,149
9 Apr 25	Marlan D Walker	Common Stock	Buy	Acquire P	No	No	0.8747	1,136	993.66	71,982
18 Feb 25	Tommy G Thompson	Common Stock	Option exercise	Acquire M	No	No	0	8,500	0.00	14,454
18 Feb 25	Tommy G Thompson	RSU Common Stock	Option exercise	Dispose M	No	No	0	8,500	0.00	0
18 Feb 25	Marlan D Walker	Common Stock	Option exercise	Acquire M	No	No	0	1,733	0.00	70,846
18 Feb 25	Marlan D Walker	Common Stock	Option exercise	Acquire M	No	No	0	770	0.00	69,113
18 Feb 25	Marlan D Walker	Common Stock	Option exercise	Acquire M	No	No	0	2,311	0.00	68,343
18 Feb 25	Marlan D Walker	Common Stock	Option exercise	Acquire M	No	No	0	3,467	0.00	66,032

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

12 Health Care Stocks Moving In Thursday's Pre-Market Session

12 Jun 25

12 Health Care Stocks Moving In Monday's Intraday Session

2 Jun 25

TherapeuticsMD Q1 EPS $(0.06) Up From $(0.07) YoY, Sales $393.00K Up From $313.00K YoY

13 May 25

TherapeuticsMD (NASDAQ:TXMD) reported quarterly losses of $(0.06) per share. This is a 14.29 percent increase over losses of $(0.07) per share from the same period last year. The company reported $393.00 thousand in

Press releases

From Benzinga Pro

TherapeuticsMD Announces Full Year 2024 Financial Results

27 Mar 25

TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ:TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2024. Full Year 2024